

RESEARCH ARTICLE

# NGF Modulates $trkA^{NGFR}/p75^{NTR}$ in $\alpha$ SMA-Expressing Conjunctival Fibroblasts from Human Ocular Cicatricial Pemphigoid (OCP)

Alessandra Micera<sup>1</sup>\*, Barbara Stampachiachiere<sup>1</sup>\*, Antonio Di Zazzo<sup>2</sup>, Roberto Sgrulletta<sup>2</sup>, Magdalena Cortes<sup>1</sup>, Eduardo Maria Normando<sup>3,4</sup>, Alessandro Lambiase<sup>5</sup>, Stefano Bonini<sup>2</sup>\*

**1** IRCCS-G.B. Bietti Foundation, Rome, Italy, **2** Department of Ophthalmology, University Campus Bio-Medico, Rome, Italy, **3** Glaucoma & Retinal Degeneration Research Group, Visual Neurosciences, UCL Institute of Ophthalmology, 11–43 Bath Street, London, EC1V 9EL, United Kingdom, **4** The Western Eye Hospital, Imperial College Healthcare Trust, Marylebone Road, London, NW1 5QH, United Kingdom, **5** Ophthalmology, Dept. Organi di senso, University of Rome “Sapienza”, Rome, Italy

\* These authors contributed equally to this work.

\* [amicera@gmail.com](mailto:amicera@gmail.com) (AM); [s.bonini@unicampus.it](mailto:s.bonini@unicampus.it) (SB)



**OPEN ACCESS**

**Citation:** Micera A, Stampachiachiere B, Di Zazzo A, Sgrulletta R, Cortes M, Normando EM, et al. (2015) NGF Modulates  $trkA^{NGFR}/p75^{NTR}$  in  $\alpha$ SMA-Expressing Conjunctival Fibroblasts from Human Ocular Cicatricial Pemphigoid (OCP). PLoS ONE 10 (11): e0142737. doi:10.1371/journal.pone.0142737

**Editor:** Andrea Caporali, University of Edinburgh, UNITED KINGDOM

**Received:** January 16, 2015

**Accepted:** October 26, 2015

**Published:** November 16, 2015

**Copyright:** © 2015 Micera et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Data Availability Statement:** All relevant data are within the paper.

**Funding:** This work was supported by the Italian Ministry of Health (MoH) and by the intramural financial support (Fondazione Roma). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing Interests:** The authors have declared that no competing interests exist. In addition, the authors would like to underline that the results

## Abstract

### Objective

In a previous study, we reported the upregulation of Nerve Growth Factor (NGF) and  $trkA^{NGFR}$  expression in Ocular Cicatricial Pemphigoid (OCP), an inflammatory and remodeling eye disease. Herein, we hypothesize a potential NGF-driven mechanism on fibroblasts (FBs) during OCP remodeling events. To verify, human derived OCP-FBs were isolated and characterized either at baseline or after NGF exposure.

### Materials and Methods

Conjunctival biopsies were obtained from 7 patients having OCP and 6 control subjects (cataract surgery). Both conjunctivas and primary FB cultures were characterised for  $\alpha$ SMA, NGF and  $trkA^{NGFR}/p75^{NTR}$  expression. Subcultures were exposed to NGF and evaluated for  $\alpha$ SMA, NGF,  $trkA^{NGFR}/p75^{NTR}$  expression as well as TGF $\beta$ 1/IL4 release. For analysis, *early* and *advanced* subgroups were defined according to clinical parameters.

### Results

OCP-conjunctivas showed  $\alpha$ SMA-expressing FBs and high NGF levels. *Advanced* OCP-FBs showed higher  $\alpha$ SMA expression associated with higher  $p75^{NTR}$  and lower  $trkA^{NGFR}$  expression, as compared to *early* counterparts.  $\alpha$ SMA expression was in keeping with disease severity and correlated to  $p75^{NTR}$ . NGF exposure did not affect  $trkA^{NGFR}$  levels in *early* OCP-FBs while decreased both  $\alpha$ SMA/ $p75^{NTR}$  expression and TGF $\beta$ 1/IL4 release. These effects were not observed in *advanced* OCP-FBs.

reported in the present manuscript are original and not submitted elsewhere.

## Conclusions

Taken together, these data are suggestive for a NGF/p75<sup>NTR</sup> task in the potential modulation of OCP fibrosis and encourages further studies to fully understand the underlying mechanism occurring in fibrosis. NGF/p75<sup>NTR</sup> might be viewed as a potential therapeutic target.

## Introduction

The Ocular Cicatricial Pemphigoid (OCP) is an immune-mediated chronic inflammatory disease of the eye, characterized by chronic-recurrent conjunctival inflammation, progressive sub-epithelial fibrosis and tissue remodeling [1–3]. Inflammatory infiltrates and activated Fibroblasts (FBs) contribute actively to the uncontrolled extracellular matrix (ECM) deposition (remodeling process), leading to structural and functional changes (keratinization and blindness) [3,4]. Several pro-inflammatory/fibrogenic cytokines and growth factors, including Transforming Growth Factor  $\beta$ 1 (TGF $\beta$ 1) and Interleukin 4 (IL4), have shown the ability to modulate the survival of activated FBs and their collagen deposition [2,5–7].

An involvement of Nerve Growth Factor (NGF) pathway in OCP has been previously reported by our group: an increased trkA<sup>NGFR</sup> immunoreactivity has been observed in OCP conjunctival stroma and a consistent NGF release has been quantified in OCP tears [8,9]. The effect of NGF in tissue remodelling and fibroblast activity is actually controversial: NGF might exert pro/anti-inflammatory effects or profibrogenic activity, acting as a “modulator” of the local immune/inflammatory response, in a receptor expression dependent manner [10–16]. In the last decade, the NGF modulatory effect on Fibroblasts (FBs) and their activated myofibroblast counterpart (myoFBs) has been prospected in view of the surface trkA<sup>NGFR</sup>/p75<sup>NTR</sup> rate expression and the NGF ability to trigger apoptosis in FBs from different tissues as well as TGF $\beta$ 1-induced myoFBs [17–21].

To address the question as whether NGF might modulate OCP-fibrosis, activated FBs and NGF immunoreactivity were verified both in tissues and cultures. Next, the study was extended to the *in vitro* characterization of OCP-FBs and the potential NGF influence on OCP-FB phenotype by monitoring  $\alpha$ SMA, trkA<sup>NGFR</sup>/p75<sup>NTR</sup> and TGF $\beta$ 1/IL4 in NGF-exposed OCP subcultures.

## Materials and Methods

### Ethics Statement

The study followed the guidelines of the Declaration of Helsinki for research involving human subjects and was approved by the intramural Ethical committee (UCBM). Informed written consent was signed by each patient adhering to the study.

### Patients and conjunctival specimens

Conjunctival biopsies were obtained from 7 patients with clinical and histological (Hematoxylin & Eosin, HE; Bio-Optica, Milan, Italy) diagnosis of OCP (2M/5F; mean age, SD, range 55–88 years) and from 6 healthy age matched patients (control group), during routine cataract surgery (5M/1F; mean age, SD, range 59–81 years).

Two fragments were produced from each biopsy: one conjunctival fragment was included in paraffin and sectioned to provide 5 $\mu$ m-sections for light/confocal microscopy, while the other fragment was used to achieve primary culture of conjunctival OCP FBs.

OCP specimens were classified according to the stage of the disease [22,23] and grouped as follows: early group comprising 3 patients (stages I or II; Foster) and advanced group including 4 patients (stages III or IV). The immunofluorescent analysis was performed for identifying the presence of a linear immunoglobulin deposition alongside the Basement Membrane Zone (BMZ), according to the specific immunoreactivity (FC-coupled IgGAM antibodies; OBT0119F; Oxford Biotech., Oxford, UK), univocally present in OCP positive sections. Basal histology included Giemsa (48900; Fluka, Milan, Italy), Haematoxylin and Eosin (HE; 05-M06014/05-M10002; Bio-Optica; Milan, Italy) as well as the Periodic Acid Schiff (PAS; 04-130802/05-M06002; Bio-Optica; Milan, Italy) stainings.

All sterile tissue culture plastic-ware and reagents were from NUNC (Roskilde, Denmark) and Serva (Heidelberg, Germany). Culture media and supplements were from Euroclone (Milan, Italy). Ultrapure/RNase free water was provided by Direct-Q5 Apparatus (Millipore, Vimodrone, Milan, Italy).

### Explants, FB subcultures and NGF studies

Conjunctival fragments were put as explants in 24-well plates and left to attach for 10min before adding DMEM supplemented with 10% heat-inactivated Fetal Bovine Serum (FBS), 1mM sodium Pyruvate, 2mM glutamine, 100U/mL penicillin and 100µg/mL streptomycin (37°C, 5% CO<sub>2</sub> in air) [17,18]. Outgrowing FBs were quickly harvested (0.2% trypsin-0.025% EDTA; HyQ trypsin; HyClone, Waltham, MA) and directly used or sub-cultured in T-21cm<sup>2</sup>/T-75cm<sup>2</sup> flasks (3<sup>rd</sup>-5<sup>th</sup> passage) for NGF exposure. The cell culture purity was estimated by the CK19 exclusion test (anti-cytokeratin 19 conjunctival epithelial marker, 1/100; Dako, Hamburg, Germany).

For stimulation studies, serum starved confluent monolayers were exposed to increasing NGF concentrations (0 to 100ng/mL β-NGF Grade I; Alomone Labs Ltd, Jerusalem, Israel) or 1ng/mL TGFβ1 (positive control; R&D system, Minneapolis, MN) performed in 0.5% FBS-DMEM for 24hrs.

Conditioned media were collected for ELISA/Western Blot analysis, while monolayers were directly processed for confocal analysis or treated with trypsin-EDTA solution to obtain single cells for molecular (10<sup>5</sup> cells) / biochemical (10<sup>6</sup> cells) analysis.

### Confocal Analysis

Conjunctival sections and monolayers were subjected to fluorescent immunostaining. Briefly, de-waxed sections and confluent monolayers on round coverslips (Mierfield, USA) were washed in Hank's Balanced Sodium Salt (HBSS), fixed in 2% buffered ρ-Formaldehyde (PFA), equilibrated in PBS [10mM phosphate buffer and 137mM NaCl; pH 7.5], briefly permeabilized with 0.5% Triton X100 in PBS (TX-PBS) and probed with the specific antibodies, either alone or in combination: mouse anti-human αSMA antibodies (1/60; Novocastra, Newcastle, UK), goat anti-human NGF antibody (sc-549; 1/100); rabbit anti-human trkA<sup>NGFR</sup> (sc-118; 1/150) and goat anti-human p75<sup>NTR</sup> (sc-6188; 1/75) antibodies (all from Santa Cruz Biotech., Santa Cruz, CA). The specific binding was detected by using Cy2/Cy3-conjugated specie-specific secondary antibodies, depending on the specific staining (1/500-1/700; Jackson ImmunoResearch Labs., Europe Ltd, Suffolk, UK). Nuclei were counterstained with Propidium Iodide (5µg/mL; ICN, Milan, Italy). Acquisitions were carried out using the E2000U confocal microscope equipped with C1 software (Nikon, Tokyo, Japan). Control sections were stained in parallel (control irrelevant IgGs; Vector Laboratories, Inc. Burlingame, CA) and used for the channel-series acquisitions (Nikon).

## Flow cytometry

Single-cells were washed in HBSS containing  $\text{Ca}^{++}/\text{Mg}^{++}$  and fixed in 3.7% buffered PFA. After washing, cells were either directly immunostained or further incubated in 70% methanol in PBS (20°C, 24hrs). For staining, cells were equilibrated in FACS buffer [0.1% saponin and 0.1%  $\text{NaN}_3$  in PBS; pH 7.5] and incubated with the above reported primary antibodies diluted in 0.1% BSA-FACS buffer. The specific binding was detected with Cy2/PE-conjugated specie-specific secondary antibodies (1/600-1/700; Jackson). Cells ( $10^4$  events) were analysed using the MACSQuant flow cytometer and cell plots were arranged using the manufacturers' provided software (Miltenyi Biotech., Gladbach, Germany). Changes in Mean Fluorescence Intensity (MFI) were calculated as follows:  $\Delta\text{MFI} = [(\text{MFI}_{\text{specific}} / \text{MFI}_{\text{not-specific}})]$  and  $\Delta\text{MFI}$  values  $\geq 1$  were used for statistical analysis.

## Relative Real-Time PCR analysis

Total RNA was extracted from confluent monolayers using the Puregene RNA purification kit (Gentra Systems, Minnesota, USA). Total RNA samples were spectrophotometrically analysed (ND-1000; NanoDrop, Wilmington, DE;  $\lambda_{260}/\lambda_{280} > 1.8$ ). Total RNA (3  $\mu\text{g}$ ) samples were reverse transcribed to a final volume of 21  $\mu\text{L}$ , using 50 pM oligo dT21-primer, 1 mM dNTP mix and 200 U reverse transcriptase (IMPROM; Promega, Milan, Italy) in a programmable PTC100 thermocycler (MJ Research, Watertown, MA) and 3  $\mu\text{L}$  were run for amplification with the specific target/referring primers in an Opticon2 MJ thermocycler (MJ Research), according to the manufacturers' instructions (Table 1). PCR experiments were carried out in a final volume of 20  $\mu\text{L}$  containing 3  $\mu\text{L}$  cDNA for target genes (or 1  $\mu\text{L}/3 \mu\text{L}$  for GAPDH/H3 reference genes) and 17  $\mu\text{L}$  of master mix [10  $\mu\text{L}$  SYBR Green PCR Mix (Applied Biosystems, Foster City, CA), 0.5  $\mu\text{L}$  of each primer (10 pM; MWG, Biotech, Ebersberg, Germany) and milliQ-water]. Amplicons were verified for their specificity according to the Southern blotting analysis. Negative controls (without template or with total RNA) were carried out for each run, to rule out any genome contamination. Single threshold cycle values (Cts) were run in the REST 384–2006 software [24] to get increase or decrease difference in target gene expression, with respect to reference genes and compared to controls. Data are gene expression ratio provided in log<sub>2</sub> scale.

## ELISA

To evaluate NGF in the culture media, a two site NGF-ELISA (0.5pg/mL sensitivity and no cross-reactivity) was carried out in Maxisorp NUNC 96 well ELISA plates precoated with mouse anti-NGF antibodies (0.4  $\mu\text{g}/\text{mL}$ ; MAB256, R&D) and incubated with standards (0.15pg/mL to 1ng/mL  $\beta$ -NGF; Alomone) or prediluted samples (1:3). The following steps included as follows: the biotinylated polyclonal anti-NGF antibodies (0.15  $\mu\text{g}/\text{mL}$ ; BAF256, R&D), the streptavidin solution (Biosource International, Camarillo, CA) and the TMB substrate (Biosource). Optical density was detected by an ELISA plate reader ( $\lambda_{450-550}$ ; Sunrise; Tecan Systems, Inc., San Jose, CA) and calculations were carried out according to the protein normalization (A280 Nanodrop) [16]. The biological activity of NGF released by OCP-FBs was verified separately by using a PC12 bioassay (see [18]).

TGF $\beta$ 1 and IL4 were measured in the conditioned media by commercially available ELISA kits, according to the manufacturers' instructions (Biosource).

## Western Blotting

Total proteins were extracted from single-cells lysed in modified RIPA buffer [50 mM Tris-HCl (pH 7.7), 150mM NaCl, 1%Triton X-100 and 0.1% SDS] freshly supplemented with



**Table 1. Primers and amplification program used in the study.**

| Primer                     | Sequence                                  | bp  | Ta*         | Accession number |
|----------------------------|---|-----|-------------|------------------|
| <b>NGF</b>                 | for 5' -CTG GCC ACA CTG AGG TGC AT-3'     | 120 | 55°C, 30sec | <b>BC011123</b>  |
|                            | rev 5' -TCC TGC AGG GAC ATT GCT CTC-3'    |     |             |                  |
| <b>trkA<sup>NGFR</sup></b> | for 5' -CAT CGT GAA GAG TGG TCT CCG-3'    | 102 | 57°C, 25sec | <b>M23102</b>    |
|                            | rev 5' -GAG AGA GAC TCC AGA GCG TTG AA-3' |     |             |                  |
| <b>p75<sup>NTR</sup></b>   | for 5' -CCT ACG GCT ACT ACC AGG ATG AG-3' | 147 | 57°C, 25sec | <b>AF187064</b>  |
|                            | rev 5' -TGG CCT CGT CGG AAT ACG-3'        |     |             |                  |
| <b>αSMA</b>                | for 5' -GAA GGA GAT CAC GGC CCT A-3'      | 125 | 55°C, 30sec | <b>BC017554</b>  |
|                            | rev 5' -ACA TCT GCT GGA AGG TGG AC-3'     |     |             |                  |
| <b>TGFβ1</b>               | for 5' -TCC TGG CGA TAC CTC AGC AA-3'     | 110 | 57°C, 25sec | <b>BC017288</b>  |
|                            | rev 5' -GCC CTC AAT TTC CCC TCC AC-3'     |     |             |                  |
| <b>GAPDH</b>               | for 5' -CCT GAC CTG CCG TCT AGA AA-3'     | 111 | 55°C, 30sec | <b>BC013310</b>  |
|                            | rev 5' -ACC TGG TGC TCA GTG TAG CC-3'     |     |             |                  |
| <b>H3</b>                  | for 5' -GCT TCG AGA GAT TCG TCG TT-3'     | 113 | 59°C, 30sec | <b>NM005324</b>  |
|                            | rev 5' -GAA ACC TCA GGT CGG TTT TG-3'     |     |             |                  |

The amplification program was as follows: 95°C/15min, followed by 47 cycles of denaturation at 94°C/15sec, annealing Ta\* at 25sec or 30sec, extension at 72°C/15sec. Melting curves for each specific primer were monitored between 60°C–90°C, at the end of amplification, before a further extension at 75°C/5min. In bold, referring gene details;

\*Ta, annealing temperature; bp, base-pairs of amplicons.

doi:10.1371/journal.pone.0142737.t001


phosphatase/protease inhibitors (Pierce). Equivalent amounts of protein (30µg) were subjected to 7–15% SDS-PAGE electrophoresis (Miniprotean3; Bio-Rad, Hercules, CA) and resolved proteins were transferred to Hy-bond membranes (semi-dry blotting apparatus; Bio-Rad). The membranes were washed in 0.05% Tween 20 in PBS (TW-PBS), blocked in 5% non-fat dry milk-PBS and probed with trkA<sup>NGFR</sup> (1/700), p75<sup>NTR</sup> (1/500), αSMA (1/500) and GAPDH (1/1000) primary antibodies, followed by secondary POD-conjugated specie-specific antibodies (1/10000; Jackson Immuneresearch). Developing was performed according to the ECL technique (SuperSignal West Pico Trial; Pierce, Rockford, IL). Bands were acquired/analysed in a Kodak Image station equipped with a 1D Image analysis software (110F; Kodak, Tokyo, Japan).

### Statistical Analysis

All experimental procedures were conducted in triplicate, each one repeated three times. Both molecular and biochemical data (means±SD) were analysed for significant differences (p < .05), by the ANOVA-Tukey-Kramer coupled post-hoc analysis (StatView II for PC; Abacus Concepts. Inc., Barkley, CA). REST-ANOVA analysis followed by Tukey Kramer posthoc comparisons was used to validate molecular data.

### Results

Only conjunctival biopsies from patients' with confirmed ophthalmic and microscopic diagnosis of OCP were included in this study. Immunofluorescent staining revealed the presence of a clear linear fluorescence alongside the BMZ, representative of autoantibodies deposition in both *early* (A) and *advanced* (B) OCP sections (Fig 1). No significant difference in IgGAM immunoreactivity was observed between *early* and *advanced* OCP, except for an increasing fluorescent signal in the epithelium and stroma (asterisk; Fig 1B). Contiguous to those IgGAM staining, basal histology was also performed by using Giemsa (Fig 1C and 1D), HE (Fig 1E and



**Fig 1. Histological characterization of OCP conjunctivas.** Representative confocal (A-B) and light microscopy (C-H) images, including Giemsa (CD), HE (EF) and PAS (GH) stainings, from dewaxed conjunctival sections. A-B. Linear fluorescent-coupled IgGAM reactivity in the Basement Membrane Zone of *early* (white arrows; A) and *advanced* (B; the white asterisk indicates the stromal immunoreactivity) OCP sections. Fluorescent linear immunoreactivity is absent in normal sections. Depletion of goblet cells (pointed by black arrowheads) in *early* (C,E,G) with respect to the complete absence in *advanced* OCP (D,F,H); the presence of a squamous metaplasia (↔) particularly in *advanced* OCP (D,F); vessel ectasia (\*) more prominent in *early* (E) than *advanced* (F); edema with mild infiltrates (arrows) in *early* (C) and to a less extend in *advanced* (D) OCP, particularly plasmacells and some granulocytes; and finally superficial homogenization of connective tissue (§), particularly evident in *advanced* OCP (D,F). Magnifications: x400.

doi:10.1371/journal.pone.0142737.g001

[1F](#)) and PAS ([Fig 1G and 1H](#)). A depletion of goblet cells was observed in *early* OCP (arrowheads) while the absence of goblet cells was detected in *advanced* OCP, as pointed in Giemsa, HE and particularly PAS panels ([Fig 1C–1H](#)). The presence of squamous metaplasia (pluri-stratified non-keratinised epithelial with absence of goblet cells and homogenization of connective tissue) was particularly evident in *advanced* OCP (see § in [Fig 1D and 1F](#)). A marked vessel

ectasia was particularly evident in *early* OCP (see asteriks in Fig 1E). Edema and mild infiltrates with prevalence of plasmacells (arrows) were observed in *early* with respect to *advanced* OCP (Fig 1C).

### Characterization of activated FBs

Adjacent conjunctival sections and primary cultures of FBs were analysed for  $\alpha$ SMA expression by confocal microscopy and flow cytometry (FCM) analysis. As shown in Fig 2,  $\alpha$ SMA immunoreactivity in outgrowth of OCP-tissue (B) and outgrew FBs (D), as compared to control specimens (respectively A and C;  $p < .05$ ). FCM analysis confirmed the higher  $\alpha$ SMA protein expression in OCP-FBs (Fig 2E;  $p < .05$ ). FCM results were corroborated at the molecular level ( $+14.00 \pm 4.80$  expression ratio in OCP-FBs vs. controls;  $p < .05$ ).


### Expression of NGF and $\text{trkA}^{\text{NGFR}}/\text{p75}^{\text{NTR}}$

OCP conjunctiva and OCP-FBs were examined for NGF- $\text{trkA}^{\text{NGFR}}/\text{p75}^{\text{NTR}}$  expression. As observed by confocal analysis, NGF expression was decreased in the epithelium and specifically increased in OCP stroma, as compared to controls (Fig 3A and 3B;  $p < .05$ ). Indeed, confocal analysis showed higher cytoplasmic and perinuclear NGF immunoreactivity in outgrew OCP-FBs, supporting those data observed in OCP stroma (see arrows; Fig 3C). In addition, the conditioned media from OCP-FBs showed higher NGF levels than those of control counterparts ( $420.00 \pm 90.00$  vs.  $220.00 \pm 64.00$  pg/mL;  $p < .05$ ), as detected by NGF ELISA. In line, NGFmRNA was increased in these OCP-FBs, as compared to their control FBs ( $+5.00 \pm 1.30$  expression ratio;  $p < .05$ ). No significant difference was quantified between *early* and *advanced* specimens.

Confocal analysis showed a high  $\text{p75}^{\text{NTR}}$  expression associated with a weak  $\text{trkA}^{\text{NGFR}}$  expression in OCP-FBs (Fig 4B). By contrary, control FBs showed a huge  $\text{trkA}^{\text{NGFR}}$  expression with respect to  $\text{p75}^{\text{NTR}}$  slightly expressed (Fig 4A). To support, the related FCM analysis for  $\text{trkA}^{\text{NGFR}}$  and  $\text{p75}^{\text{NTR}}$  are provided in Fig 4C and 4D respectively.

### $\alpha$ SMA and $\text{p75}^{\text{NTR}}$ co-expression in OCP-derived activated FBs

The higher  $\alpha$ SMA and  $\text{p75}^{\text{NTR}}$  and the lower  $\text{trkA}^{\text{NGFR}}$  protein expressions in OCP-FBs were also detected by WB analysis, as compared to control FBs (Fig 5A;  $p < 0.05$ ). As shown in Fig 5B,  $\alpha$ SMA protein co-localized with  $\text{p75}^{\text{NTR}}$  but not with  $\text{trkA}^{\text{NGFR}}$ , as detected by confocal analysis. This would suggest the existence of a specific  $\text{trkA}^{\text{NGFR}}/\text{p75}^{\text{NTR}}$  expression ratio during the progress of fibrosis. Particularly, basal histology showed a strong infiltration of inflammatory cells (arrows pointing to plasmacells in Fig 1C), the presence of connective tissue homogenization (asterisk in 1D and 1F) in the underlying stroma (§) and a significant decrease (absence) of goblet cells in the epithelium of *advanced* OCP sections (see arrowheads pointing residual goblet cells in *early* OCP) (Fig 1C and 1E). Activated fibroblast were also visible in *early* OCP (Fig 1C). No significant difference in  $\alpha$ SMA,  $\text{p75}^{\text{NTR}}$  and  $\text{trkA}^{\text{NGFR}}$  transcripts was detected in *early* OCP-FBs compared to controls (respectively  $+1.05 \pm 0.05$ ,  $+1.30 \pm 0.50$  and  $+2.00 \pm 1.00$  expression ratio;  $p > .05$ ). In *advanced* OCP-FBs,  $\alpha$ SMA and  $\text{p75}^{\text{NTR}}$  transcripts were significantly increased ( $+9.00 \pm 0.40$  and  $+5.00 \pm 0.50$  expression ratio;  $p < .001$ ) while  $\text{trkA}^{\text{NGFR}}$  transcript was significantly decreased ( $-4.00 \pm 1.00$  expression ratio;  $p < .05$ ), as compared to controls. By FCM analysis,  $\alpha$ SMA protein was increased in *early* OCP-FBs ( $2.8 \pm 0.58$  vs.  $0.22 \pm 0.06$  MFI, *early* vs. controls;  $p > .05$ ) and significantly increased in *advanced* OCP-FBs ( $27.05 \pm 3.6$  vs.  $0.22 \pm 0.06$  MFI, *advanced* vs. controls;  $p < .001$ ). Indeed,  $\text{p75}^{\text{NTR}}$  protein was increased in both *early* ( $15.52 \pm 5.97$  vs.  $1.44 \pm 0.6$  MFI, *early* vs. controls;  $p < .05$ ) and *advanced* ( $17.0 \pm 3.0$  vs.  $1.44 \pm 0.6$  MFI, *advanced* vs. controls;  $p < .01$ ) OCP-FBs. Finally,  $\text{trkA}^{\text{NGFR}}$  protein



**Fig 2.  $\alpha$ SMA expression in both OCP conjunctiva and derived FBs.** A-D. Confocal analysis for  $\alpha$ -SMA in both control (A) and OCP (B) conjunctival biopsies, as well as in control (C) and OCP (D) FB. Arrows point to specific  $\alpha$ -SMA immunoreactivity in OCP tissue (B; red staining; see [M&M](#) for details). In monolayers, nuclei were counterstained with propidium iodide (C-D). [Magnifications: AB, x400; CD, x600] E-F. Flow cytometry analysis specific for  $\alpha$ -SMA in control (E) and OCP (F) FBs. iso = fluorescence intensity related to isotypes.


doi:10.1371/journal.pone.0142737.g002

expression in *early* OCP-FBs was comparable to those of control-FBs while it decreased in *advanced* OCP-FBs ( $2.41 \pm 1.27$  vs.  $15.5 \pm 1.00$  MFI, *advanced* vs. controls;  $p < .01$ ).

### NGF modulation of $\alpha$ SMA and $trkA^{NGFR}/p75^{NTR}$ expression in OCP-FBs

NGF effect on  $\alpha$ SMA and  $trkA^{NGFR}/p75^{NTR}$  modulation was thereafter investigated by exposure to 10ng/mL NGF over 24hrs. A preliminary dose response study was carried out on OCP-FBs (0–100 ng/mL NGF over 24hrs), highlighting the 10 ng/mL NGF dosage. In *early* OCP-FBs, decreased  $\alpha$ SMA and  $p75^{NTR}$  (respectively  $0.83 \pm 0.19$  vs.  $2.8 \pm 0.58$  MFI and 1.08





**Fig 3. NGF immunoreactivity in OCP conjunctiva and FBs.** Confocal analysis for NGF (green) in control (A) and OCP (B,C) conjunctiva. C. Immunofluorescence for NGF (red) and  $\alpha$ SMA (green) expression in the conjunctival stroma. Note the presence of intracytoplasm and perinuclear staining. Nuclei were counterstained with toto3. Magnifications: AB, x400; C, x600 (oil immersion).

doi:10.1371/journal.pone.0142737.g003


$\pm 0.56$  vs.  $15.52 \pm 5.97$  MFI;  $p < .05$ ) as well as unchanged  $trkA^{NGFR}$  ( $20.33 \pm 8.52$  vs.  $20.93 \pm 4.87$  MFI;  $p > .05$ ) protein expressions were observed upon NGF exposure. In *advanced* OCP-FBs, no significant changes of  $\alpha$ SMA and  $p75^{NTR}$  (respectively  $17.60 \pm 1.15$  vs.  $17.00 \pm 6.12$  and  $31 \pm 4.77$  vs.  $26.83 \pm 3.84$  MFI;  $p > .05$ ) as well as  $trkA^{NGFR}$  ( $2.93 \pm 0.83$  vs.  $2.41 \pm 1.27$  MFI;  $p > .05$ ) protein expressions were detected upon NGF exposure. With respect to  $trkA^{NGFR}/p75^{NTR}$  expression, FCM analysis showed that 94.91% *early* OCP-FBs were  $trkA^{NGFR}$  positive, with 57.24% co-expressing  $p75^{NTR}$ . Upon NGF exposure, 96.88% *early* OCP-FBs were still  $trkA^{NGFR}$  positive, with 24.12% co-expressing  $p75^{NTR}$  and 72.76% expressing only  $trkA^{NGFR}$ . The statistical analysis showed that a decrease of 57% in  $trkA^{NGFR}/p75^{NTR}$  co-expressing cells occurred in association with a shift to  $trkA^{NGFR}$  expressing cells. The  $trkA^{NGFR}/p75^{NTR}$  immunoreactivity in NGF exposed *early* OCP-FBs is shown (Fig 6).

### NGF modulation of OCP-activated FBs derived TGF $\beta$ 1 and IL4 cytokines

Last, changes in TGF $\beta$ 1 and IL4 profibrogenic factor release were also detected in the conditioned media from baseline and NGF treated OCP-FBs. TGF $\beta$ 1 and IL4 levels in the conditioned media from *early* OCP-FBs were respectively 8-times ( $101.00 \pm 30.00$  vs.  $12.00 \pm 2.10$  pg/mL TGF $\beta$ 1,  $p < .05$ ) and 6-times ( $308.00 \pm 7.00$  vs.  $55.00 \pm 40.00$  pg/mL IL4;  $p < .001$ ) higher as compared to control counterparts. Conditioned media from *advanced* OCP-FBs did not show difference in both TGF $\beta$ 1 and IL4 levels, as compared to controls. Upon 10ng/mL NGF exposure, IL4 protein decreased in the conditioned media from *early* ( $26.00 \pm 10.00$  vs.  $101.00 \pm 30.00$  pg/mL IL4;  $p < .05$ ) and *advanced* ( $1.80 \pm 0.30$  vs.  $23.00 \pm 4.80$  pg/mL IL4;  $p < .05$ ) OCP-FBs. By contrary, TGF $\beta$ 1 levels decreased only in the conditioned media from *early* OCP-FBs ( $63.00 \pm 40.00$  vs.  $308.00 \pm 7.00$  pg/mL TGF $\beta$ 1;  $p < .05$ ).

### Discussion

Increasing data indicate that the chronic inflammatory process occurring in OCP conjunctiva leads to FB activation and survival, with overt collagen deposition and excessive matrix deposition [3]. As a product of different structural/immune cells and FBs/myoFBs, both cytokines and growth factors actively contribute to subepithelial fibrosis and conjunctival scarring [25]. To date, different proinflammatory and profibrogenic factors have been investigated by different groups, which have focused their attention especially on receptor signalling [26]. While in a previous study we have described the  $trkA^{NGFR}$  and NGF expression respectively in OCP




**Fig 4.  $trkA^{NGFR}$  and  $p75^{NTR}$  in OCP conjunctiva and FBs.** AB. Confocal analysis of control (A) and OCP (B) FBs double (overlays; x400) and single stained for  $trkA^{NGFR}$  and  $p75^{NTR}$  (see below). Relevant single immunoreactions are shown below and cross-reactivity of  $trkA^{NGFR}$  and  $p75^{NTR}$  are marked with white arrows (overlays). CD: Flow cytometry analysis of control (left) and OCP (right) FBs showing expression of  $trkA^{NGFR}$  (C) and  $p75^{NTR}$  (D). Related isotype fluorescence intensity data are shown (iso).

doi:10.1371/journal.pone.0142737.g004

conjunctivas and tears, herein we hypothesize a possible NGF role in the modulation of cultured OCP-FBs [8,9].

First of all,  $\alpha$ SMA expression was detected in OCP conjunctiva and confirmed in primary cultures of FBs obtained from OCP explants.  $\alpha$ SMA ( $\alpha$ -Smooth Muscle Actin) represents the most reliable phenotypic marker for the majority of fibrotic states. Our findings indicate the presence of activated FBs inside inflamed/fibrotic OCP conjunctiva [7,27,28]. If these activated






**Fig 5.  $\alpha$ SMA and  $trkA^{NGFR}/p75^{NTR}$  expression in OCP-FBs.** A. Representative Western blot analysis specific for  $\alpha$ SMA,  $p75^{NTR}$  and  $trkA^{NGFR}$  proteins in control (left) and OCP (right) FBs ( $n = 2$ /each group). Normalization was checked by GAPDH reprobing on the same gels. BC. Confocal analysis for  $\alpha$ -SMA/ $trkA^{NGFR}$  (B) and  $\alpha$ -SMA/ $p75^{NTR}$  (C) in OCP-FBs (overlays, x600). Respective single immunoreactions are shown below.  $p75^{NTR}$  and  $\alpha$ -SMA cross-reactivity is highlighted with white arrows (C).

doi:10.1371/journal.pone.0142737.g005

FBs are  $\alpha$ SMA-expressing myofibroblast (myoFBs) remains to be clarified since in previous studies the possible differentiation of OCP-FBs into myoFBs was not reported [29].

An increase in the stroma and a significant decrease in the epithelium were detected for NGF in OCP conjunctival biopsies ( $n = 7$ ), as compared to control ones. To the best of our knowledge, this data has not been previously described and it is supported by our recent findings showing an increased NGF content in OCP tear fluids [8,9]. The observation of NGF-expressing OCP-FBs might suggest that the NGF increase in OCP stroma as well as the increased NGF levels in OCP tears might be partially due to local activated-FBs. On the other

## NGF exposed FBs



## early OCP

**Fig 6.**  $trkA^{NGFR}/p75^{NTR}$  expression in NGF exposed early OCP-FBs. Confocal images showing the  $trkA^{NGFR}$  (FC/green, A) and  $p75^{NTR}$  (Cy5/blue, B) immunoreactivity in early OCP-FBs exposed to NGF over 24hrs (overlays, C). Nuclei counterstained with propidium iodide are shown in all panels. The cytoplasmic and perinuclear distribution of both receptors is clearly visible. Magnifications: A-C, x400.

doi:10.1371/journal.pone.0142737.g006

side, the decreased NGF immunoreactivity in OCP epithelium is actually missing of explanation and not investigated/discussed in this study.

As product of stromal inflammation, it is reasonable to hypothesize that NGF might contribute to tissue remodeling by influencing the FB phenotype, as observed in previous studies conducted on other cell types [14,17,18,20]. With respect to the activated FB phenotype, NGF effects might cover either cell survival and/or soluble mediator release [14,17]. According to literature, NGF activity is driven by  $trkA^{NGFR}$  and  $p75^{NTR}$  receptors, which mediate NGF signal alone or in cooperation [30–35]. As a new finding, NGF,  $trkA^{NGFR}/p75^{NTR}$  and  $\alpha$ SMA (co) expressions were detected in primary cell cultures alongside with sub-cultured OCP-FBs. Of interest, sub-cultured OCP-FBs showed the ability to retain FB phenotype upon few passages and were therefore suitable for stimulation studies. Interestingly,  $trkA^{NGFR}/p75^{NGF}$  expression was found strictly dependent to the *early/advanced* grouping of disease as well as  $\alpha$ SMA phenotype correlated to  $p75^{NTR}$  and paralleled the severity of fibrosis. Particularly, FBs from *advanced* OCP showed higher  $\alpha$ SMA and  $p75^{NTR}$  together with lower  $trkA^{NGFR}$ , as compared to *early* and control counterparts. This expression would imply a close association of  $p75^{NTR}$  with OCP-FB phenotype, and highlight a possible modulation of myoFB apoptosis, as observed in other systems [20,35]. To date, the role of  $trkA^{NGFR}$  and  $p75^{NTR}$  in tissue remodeling remains controversial. As documented, both  $trkA^{NGFR}$  and  $p75^{NTR}$  can mediate either survival or apoptosis, depending on their surface receptor (co)expression and microenvironment [33,36–38]. In early healing process, high levels of  $trkA^{NGFR}$  might drive both migration and differentiation (as initial matrix remodelling) while in late healing process the  $trkA^{NGFR}$  down-regulation might allow  $p75^{NTR}$  to mediate other biological activities, alone or eventually in cooperation with  $trkA^{NGFR}$  [33,39–41]. As described, fibrotic tissues appear characterized by low  $trkA^{NGFR}$  and high  $p75^{NTR}$  expression [17,18,20]. In this study, a higher  $trkA^{NGFR}/p75^{NTR}$  ratio (the outcome of a  $trkA^{NGFR}$  over-expression) was observed in *early* OCP-FBs while lower  $trkA^{NGFR}/p75^{NTR}$  ratio (the outcome of an increased  $p75^{NTR}$  expression) was detected in

*advanced* OCP-FBs, according to the clinical and histological features (infiltrates and remodeling features) [2,22,42]. To support our findings, the lower  $\text{trkA}^{\text{NGFR}}/\text{p75}^{\text{NTR}}$  ratio expression in *advanced* OCP-FBs (the outcome of an increased  $\text{p75}^{\text{NTR}}$  expression) has been also reported in other fibrotic conditions, either *in vitro/ex vivo* [7,17,18,28,43]. A down-regulation of both  $\alpha\text{SMA}$  and  $\text{p75}^{\text{NTR}}$  expression was observed in NGF-exposed *early* OCP-FBs, while no effect was detected in NGF-exposed *advanced* counterpart. The observation that NGF modulated  $\text{trkA}^{\text{NGFR}}/\text{p75}^{\text{NTR}}$  ratio expression preferentially in early OCP-FBs would suggest that a potential control of activated FBs might be possible in early OCP showing a mild-moderate clinical facet, opening to potential NGF therapeutic applications. As shown, activated FBs disappear alongside “proper repair process” while  $\alpha\text{SMA}$ -expressing activated FBs survive in pathological remodelling [7,28]. This process might be highly regulated by growth factors and cytokines, including NGF, all known to be increased in OCP tissues and tears [5,6,8,9]. Therefore, a possible cross-talk between NGF and other profibrogenic factors cannot be excluded. In line, TGF $\beta$ 1 and IL4 were extensively investigated in fibrosis and are widely reported to contribute selectively to tissue remodelling and overt fibrosis in different disorders via an extensive sustaining of myoFBs [2,6,28,44]. Therefore, we wonder whether NGF might influence TGF $\beta$ 1 and IL4 release from sub-cultures of OCP-FBs. The biochemical analysis highlighted a significant decrease of TGF $\beta$ 1 and IL4 in the conditioned media from NGF-exposed *early* OCP-FBs, while only a decrease of IL4 was monitored in *advanced* counterparts. This selective effect holds up the potential NGF involvement in OCP remodelling, through a modulation of inflammatory/fibrogenic soluble factors, at least in *early* stage of disease.

Overall, OCP is a chronic inflammatory disease that slowly evolves in severe conjunctival scarring and visual impairments [1,2,45]. Most of the current OCP therapies target the suppression of inflammation, as counteracting the recurrent inflammation represents the main way to reduce progressive remodelling [46–48]. The findings of this *in vitro* study suggest a possible NGF effect on early OCP-FBs having a low  $\text{trkA}^{\text{NGFR}}/\text{p75}^{\text{NTR}}$  ratio, highlighting the possible NGF effect in the modulation of FB activity during the *early* stages of disease. Since the topical NGF application has been suggested as a therapeutic tool in some ocular surface disorders [11,49], these findings encourage further studies to understand the underlying NGF mechanism in OCP conjunctiva in order to develop alternative strategies to counteract fibrosis.

## Acknowledgments

The data of this study were partially presented at the Annual Meeting of the Association for Research in Vision and Ophthalmology, 2007, Fort-Lauderdale, Florida (Stampachiacchiere et al., *Invest. Ophthalmol. Vis. Sci.* 2007 48: E-Abstract 5306). This study was partially supported by Ministry of Health (Italy). The authors wish to express gratitude to Fondazione Roma for continuous support. Special thanks to Dr. Eleonora Perrella for her valuable contribution (Pathology, UCBM).

## Author Contributions

Conceived and designed the experiments: AM BS AL SB. Performed the experiments: AM BS ADZ RS EMN AL SB. Analyzed the data: AM BS ADZ RS MC AL SB. Contributed reagents/materials/analysis tools: AM SB. Wrote the paper: AM BS AL SB.

## References

1. Ahmed M, Zein G, Khawaja F, Foster CS. Ocular cicatricial pemphigoid: pathogenesis, diagnosis and treatment. *Prog Retin Eye Res* 2004; 23: 579–592. PMID: [15388075](#)

2. Foster CS, Sainz De La Maza M. Ocular cicatricial pemphigoid review. *Curr Opin Allergy Clin Immunol* 2004; 4: 435–439. PMID: [15349045](#)
3. Razzaque MS, Foster CS, Ahmed AR. Tissue and molecular events in human conjunctival scarring in ocular cicatricial pemphigoid. *Histol Histopathol* 2001; 16: 1203–1212. PMID: [11642740](#)
4. Kirzhner M, Jakobiec FA. Ocular cicatricial pemphigoid: a review of clinical features, immunopathology, differential diagnosis, and current management. *Semin Ophthalmol* 2011; 26: 270–277. doi: [10.3109/08820538.2011.588660](#) PMID: [21958173](#)
5. Razzaque MS, Foster CS, Ahmed AR. Role of connective tissue growth factor in the pathogenesis of conjunctival scarring in ocular cicatricial pemphigoid. *Invest Ophthalmol Vis Sci* 2003; 44: 1998–2003. PMID: [12714635](#)
6. Razzaque MS, Ahmed BS, Foster CS, Ahmed AR. Effects of IL-4 on Conjunctival Fibroblasts: Possible Role in Ocular Cicatricial Pemphigoid. *Invest Ophthalmol Vis Sci* 2003; 44: 3417–3423. PMID: [12882790](#)
7. Desmouliere A, Darby IA, Gabbiani G. Normal and pathologic soft tissue remodeling: role of the myofibroblast, with special emphasis on liver and kidney fibrosis. *Lab Invest* 2003; 83: 1689–1707. PMID: [14691287](#)
8. Lambiase A, Bonini S, Micera A, Rama P, Bonini S, Aloe L. Expression of nerve growth factor receptors on the ocular surface in healthy subjects and during manifestation of inflammatory diseases. *Invest Ophthalmol Vis Sci* 1998; 39: 1272–1275. PMID: [9620090](#)
9. Lambiase A, Micera A, Sacchetti M, Cortes M, Mantelli F, Bonini S. Alterations of tear neuromediators in dry eye disease. *Arch Ophthalmol* 2011; 129: 981–986. doi: [10.1001/archophthalmol.2011.200](#) PMID: [21825181](#)
10. Levi-Montalcini R. The saga of the nerve growth factor. *Neuroreport* 1998; 9: 71–83.
11. Aloe L, Micera A. Nerve Growth Factor: Basic finding and clinical trials. *Biomedical Reviews* 1999; 10: 3–14.
12. Bonini S, Lambiase A, Bonini S, Levi-Schaffer F, Aloe L. Nerve growth factor: an important molecule in allergic inflammation and tissue remodelling. *Int Arch Allergy Immunol* 1999; 118: 159–162. PMID: [10224366](#)
13. Chao MV. Neurotrophins and their receptors: a convergence point for many signalling pathways. *Nat Rev Neurosci* 2003; 4: 299–309. PMID: [12671646](#)
14. Micera A, Lambiase A, Aloe L, Bonini S, Levi-Schaffer F, Bonini S. Nerve growth factor involvement in the visual system: implications in allergic and neurodegenerative diseases. *Cytokine Growth Factor Rev* 2004; 15: 411–417. PMID: [15561599](#)
15. Micera A, Lambiase A, Stampaciacchiere B, Sgrulletta R, Normando EM, Bonini S et al. Nerve growth factor has a modulatory role on human primary fibroblast cultures derived from vernal keratoconjunctivitis-affected conjunctiva. *Mol Vision* 2007; 13: 981–987.
16. Hempstead BL. Dissecting the diverse actions of pro- and mature neurotrophins. *Curr Alzheimer Res* 2006; 3: 19–24. PMID: [16472198](#)
17. Micera A, Lambiase A, Stampaciacchiere B, Bonini S, Bonini S, Levi-Schaffer F. Nerve growth factor and tissue repair remodeling: trkA(NGFR) and p75(NTR), two receptors one fate. *Cytokine Growth Factor Rev* 2007; 18: 245–256. PMID: [17531524](#)
18. Micera A, Vigneti E, Pickholtz D, Reich R, Pappo O, Bonini S, et al. Nerve growth factor displays stimulatory effects on human skin and lung fibroblasts, demonstrating a direct role for this factor in tissue repair. *Proc Natl Acad Sci USA* 2001; 98: 6162–6167. PMID: [11344264](#)
19. Kendall TJ, Henedige S, Aucott RL, Hartland SN, Vernon MA, Benyon RC, et al. p75 Neurotrophin receptor signaling regulates hepatic myofibroblast proliferation and apoptosis in recovery from rodent liver fibrosis. *Hepatology* 2009; 49: 901–910. doi: [10.1002/hep.22701](#) PMID: [19072833](#)
20. Trim N, Morgan S, Evans M, Issa R, Fine D, Afford S, et al. Hepatic stellate cells express the low affinity nerve growth factor receptor p75 and undergo apoptosis in response to nerve growth factor stimulation. *Am J Pathol* 2000; 156: 1235–1243. PMID: [10751349](#)
21. Lee R, Kermani P, Teng KK, Hempstead BL. Regulation of cell survival by secreted proneurotrophins. *Science* 2001; 294: 1945–1948. PMID: [11729324](#)
22. Mondino BJ, Brown SI. Ocular cicatricial pemphigoid. *Ophthalmology* 1981; 88: 95–100. PMID: [7015218](#)
23. Williams GP, Radford C, Nightingale P, Dart JK, Rausz S. Evaluation of early and late presentation of patients with ocular mucous membrane pemphigoid to two major tertiary referral hospitals in the United Kingdom. *Eye* 2011; 25: 1207–1218. doi: [10.1038/eye.2011.175](#) PMID: [21799523](#)
24. Pfaffl MW, Horgan GW, Dempfle L. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. *Nucleic Acids Res* 2002; 30: e36. PMID: [11972351](#)

25. Jelaska A, Strehlow D, Korn JH. Fibroblast heterogeneity in physiological conditions and fibrotic disease. *Springer Semin Immunopathol* 1999; 21: 385–395. PMID: [10945032](#)
26. Wynn TA, Ramalingam TR. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. *Nature Medicine* 2012; 18: 1028–1040. doi: [10.1038/nm.2807](#) PMID: [22772564](#)
27. Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C, Brown RA. Myofibroblasts and mechano-regulation of connective tissue remodelling. *Nat Rev Mol Cell Biol* 2002; 3: 349–363. PMID: [11988769](#)
28. Hinz B. Formation and function of the myofibroblast during tissue repair. *J Invest Dermatol* 2007; 127: 526–537. PMID: [17299435](#)
29. Saw VP, Schmidt E, Offiah I, Galatowicz G, Zillikens D, Dart JK, et al. Profibrotic phenotype of conjunctival fibroblasts from mucous membrane pemphigoid. *Am J Pathol* 2011; 178: 187–197. doi: [10.1016/j.ajpath.2010.11.013](#) PMID: [21224056](#)
30. Sofroniew MV, Howe CL, Mobley WC. Nerve growth factor signaling, neuroprotection, and neural repair. *Annu Rev Neurosci* 2001; 24: 1217–1281. PMID: [11520933](#)
31. Mahadeo D, Kaplan L, Chao MV, Hempstead BL. High affinity nerve growth factor binding displays a faster rate of association than p140trk binding. Implications for multi-subunit polypeptide receptors. *J Biol Chem* 1994; 269: 6884–6891. PMID: [8120051](#)
32. Bibel M, Hoppe E, Barde YA. Biochemical and functional interactions between the neurotrophin receptors trk and p75NTR. *EMBO J* 1999; 18: 616–622. PMID: [9927421](#)
33. Zampieri N, Chao MV. Mechanisms of neurotrophin receptor signalling. *Biochem Soc Trans* 2006; 34: 607–611. PMID: [16856873](#)
34. Nykjaer A, Willnow TE, Petersen CM. p75NTR-live or let die. *Curr Opin Neurobiol* 2005; 15: 49–57. PMID: [15721744](#)
35. Passino MA, Adams RA, Sikorski SL, Akassoglou K. Regulation of hepatic stellate cell differentiation by the neurotrophin receptor p75NTR. *Science* 2007; 315: 1853–1856. PMID: [17395831](#)
36. Matrone C, Marolda R, Ciafrè S, Ciotti MT, Mercanti D, Calissano P. Tyrosine kinase nerve growth factor receptor switches from prosurvival to proapoptotic activity via Abeta-mediated phosphorylation. *Proc Natl Acad Sci U S A* 2009; 106: 11358–11363. doi: [10.1073/pnas.0904998106](#) PMID: [19549834](#)
37. Zhou Y, Lu TJ, Xiong ZQ. NGF-dependent retrograde signaling: survival versus death. *Cell Res* 2009; 19: 525–526. doi: [10.1038/cr.2009.47](#) PMID: [19421238](#)
38. Kraft AD, McPherson CA, Harry GJ. Heterogeneity of microglia and TNF signaling as determinants for neuronal death or survival. *Neurotoxicology* 2009; 30: 785–793. doi: [10.1016/j.neuro.2009.07.001](#) PMID: [19596372](#)
39. Barker PA. p75NTR is positively promiscuous: novel partners and new insights. *Neuron* 2004; 42: 529–533. PMID: [15157416](#)
40. Teng KK, Hempstead BL. Neurotrophins and their receptors: signaling trios in complex biological systems. *Cell Mol Life Sci* 2004; 61: 35–48. PMID: [14704852](#)
41. Schor NF. The p75 neurotrophin receptor in human development and disease. *Prog Neurobiol* 2005; 77: 201–214. PMID: [16297524](#)
42. Elder MJ, Bernauer W, Leonard J, Dart JK. Progression of disease in ocular cicatricial pemphigoid. *British Journal of Ophthalmology* 1996; 80: 292–296. PMID: [8703876](#)
43. Chen K, Wei Y, Sharp GC, Braley-Mullen H. Balance of proliferation and cell death between thyrocytes and myofibroblasts regulates thyroid fibrosis in granulomatous experimental autoimmune thyroiditis (GEAT). *J Leukoc Biol* 2005; 77: 166–172. PMID: [15536125](#)
44. Border WA, Noble NA. Mechanisms of disease: transforming growth factor (beta) in tissue fibrosis. *N Engl J Med* 1994; 331: 1286–1292. PMID: [7935686](#)
45. Sgrulletta R, Lambiase A, Micera A, Bonini S. Corneal ulcer as an atypical presentation of ocular cicatricial pemphigoid. *Eur J Ophthalmol* 2007; 17: 121–123. PMID: [17294392](#)
46. Miserocchi E, Baltatzis S, Roque MR, Ahmed AR, Foster CS. The effect of treatment and its related side effects in patients with severe ocular cicatricial pemphigoid. *Ophthalmology* 2002; 109: 111–118. PMID: [11772589](#)
47. Sacher C, Hunzelmann N. Cicatricial pemphigoid (mucous membrane pemphigoid): current and emerging therapeutic approaches. *Am J Clin Dermatol* 2005; 6: 93–103. PMID: [15799681](#)
48. Durrani K, Zakka FR, Ahmed M, Memon M, Siddique SS, Foster CS. Systemic therapy with conventional and novel immunomodulatory agents for ocular inflammatory disease. *Surv Ophthalmol* 2011; 56: 474–510. doi: [10.1016/j.survophthal.2011.05.003](#) PMID: [22117884](#)
49. Lambiase A, Mantelli F, Sacchetti M, Rossi S, Aloe L, Bonini S. Clinical applications of NGF in ocular diseases. *Arch Ital Biol* 2011; 149: 283–292. doi: [10.4449/aib.v149i2.1363](#) PMID: [21702001](#)